ArticleScientific reports2025
Antiarthritic activities of berberine in a rat model of gouty arthritis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Sustained Intra-Articular Delivery of Triple Therapeutics Using a Phase-Transition Phospholipid-Based Gel for Effective Treatment of Gouty Arthritis.Pharmaceutical research · 2026Article
- Evaluation of the quality of information on gouty arthritis on Chinese internet platforms: A cross-sectional comparative analysis.Medicine · 2026Article
- The gut-joint axis in gout: microbial outer membrane vesicles and mFrontiers in immunology · 2026Review
- Gouty arthritis model: delving into disease pathways and uncovering possible therapeutic targets.Frontiers in endocrinology · 2026Review
- Anti-arthritic activities of cross-linked hyaluronic acid-dexamethasone hydrogel in a rat model of gouty arthritis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gouty arthritis (GA) is an inflammatory arthritic disorder that is characterized by intense, acute inflammatory responses, such as synovitis and arthritis that occur due to articular deposition of monosodium urate (MSU) crystals. This study has compared the therapeutic potentials of either Berberine (BERB) or Paracetamol (Para) on MSU-induced inflammation in rat model of Gouty arthritis (GA). GA was induced by "intra-articular" injection of MSU suspension (20 mg/ml) inside the knee joint of the rat's right limb. Circumference was measured at 48 h after MSU injection and 14 days post-treatment with BERB or Para. Gait assessment was conducted. Histopathological alterations of knee and paw (ankle) joint tissue were investigated. Serum levels of Malondialdehyde (MDA), monocyte chemotactic protein 1 (MCP-1), Vascular endothelial growth factor (VEGF), and prostaglandin E2 (PGE2) were estimated. Molecular analysis of Elastase, Cyclooxygenase-2 (COX-2), Matrix metalloproteinase-9 (MMP-9), and Myeloperoxidase (MPO) was evaluated. In addition, DNA fragmentation assay was performed. Our results revealed that deposition of MSU crystals in the articular joints provoked an inflammatory response, oxidative stress, and DNA fragmentation (apoptosis). However, the oral treatment of MSU-induced rats with either BERB (50 mg/kg/day) or Para (50 mg/kg/day) for 14 days mitigated MSU-stimulated inflammation and arthritis as represented by the behavioral, histopathological, biochemical, and molecular levels. Treatment of MSU-induced arthritic rats with BERB or Para attenuated oedema and alleviated histological signs of acute inflammation. In addition, treatment decreased chemokine levels and reduced MDA levels. These results indicated that BERB and Para exerted strong anti-inflammatory, anti-oxidative, and anti-apoptotic activities against GA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.